MiMedx Group Inc
NASDAQ:MDXG

Watchlist Manager
MiMedx Group Inc Logo
MiMedx Group Inc
NASDAQ:MDXG
Watchlist
Price: 6.93 USD 2.51% Market Closed
Market Cap: 1B USD

EV/EBITDA
Enterprise Value to EBITDA

18.6
Current
16.8
Median
5.1
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
18.6
=
Enterprise Value
934m USD
/
EBITDA
50.2m USD
EBITDA Growth EV/EBITDA to Growth
US
MiMedx Group Inc
NASDAQ:MDXG
Average EV/EBITDA: 16.7
18.6
23%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 491.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 213.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.8
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.9 N/A N/A
AU
CSL Ltd
ASX:CSL
19.1
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
11.8
2-Years Forward
EV/EBITDA
10.1
3-Years Forward
EV/EBITDA
8.8